Canon Stock And 2 Japanese Dividend Shares For Reliable Income

Government bond yields across Europe are climbing as inflation concerns and Iran US tensions keep investors focused on higher for longer interest rates. That shift is putting fresh attention on reliable income from equities. Dividend powerhouses with yields above 5% and well covered, stable payouts can help investors maintain cash flow even as bond markets reset. This article highlights three such stocks from the screener.

The three dividend powerhouses in this article are only a starting sample, and the full screen surfaced 454 more companies with similarly robust income profiles and compelling narratives that are not covered below. To identify and analyze the highest conviction opportunities for your own watchlist, go straight to the Dividend Powerhouses (3%+ Yield) screener.

Canon (TSE:7751)

Overview: Canon is a global manufacturer of printers, medical equipment and imaging products, with its Printing Business Unit, including office printers and consumables, providing the most direct link to the Dividend Powerhouses theme through steady cash generation that supports its dividend. The company also operates sizeable medical, imaging and industrial equipment businesses, so the dividend story is not tied to printing alone, even if that segment is a key cash engine.

Operations: Canon generates most of its revenue from Printing at about ¥2,513b, with additional contributions from Imaging at about ¥1,135b, Medical at about ¥579b and Industrial at about ¥347b.

Market Cap: ¥3,874b

Investors looking at Canon get a combination of a high yielding dividend profile and a business that still throws off substantial cash from office and production printing, where consumables and service contracts can be relatively predictable. Recent half year results to June 2026 showed revenue of ¥2,274,542m and net income of ¥171,184m, which supports the case that earnings currently back the payout. A share buyback program that has already retired more than 4% of stock points to a shareholder friendly capital return mindset. The main watchpoints are Canon’s uneven dividend history and some board independence concerns, which leave questions about how consistently that cash will be shared with investors over time.

Canon’s cash rich printing engine and shareholder returns story can look straightforward at first glance, yet the real tension is how long that income strength lasts. Get the full picture in the 4 key rewards and 1 important warning sign

Build your own dividend powerhouse shortlist

Canon and the two other stocks in this list were all surfaced using a single screener, but the real value comes when you shape the filters yourself. Use our customisable Screener to combine dividend strength, balance sheet quality and valuation into your own watchlist, or tap into our curated Investing Ideas.

Tokio Marine Holdings (TSE:8766)

Overview: Tokio Marine Holdings is a global insurer that sells a wide range of non life and life insurance products, using the steady premium income and investment returns from these policies to support a well covered dividend that fits the Dividend Powerhouses theme. Beyond core property and casualty insurance, the group also offers specialist cover such as catastrophe, cyber, trade credit and carbon related risk, which helps diversify earnings that underpin its shareholder payouts.

Operations: Tokio Marine generates most of its revenue from Overseas Insurance Business at about ¥5,408b and Domestic Property and Casualty Insurance at about ¥3,163b, with smaller contributions from Domestic Life Insurance at about ¥445b and Solution and Other Business at about ¥328b.

Market Cap: ¥14,214b

Tokio Marine offers investors a mix of a 3.31% dividend yield, clear dividend growth guidance into 2027 and regular buybacks that together point to a consistent income and capital return story backed by a large global insurance franchise. The Re New program and broader transformation aim to make the business leaner and more profitable, while expanding solution areas such as disaster resilience and carbon risk cover that could deepen long term client relationships. That said, plans to lift returns rely partly on selling legacy equity holdings and finding suitable M&A targets at rich valuations, and exposure to international credit and catastrophe risk can still unsettle earnings. For investors who want dependable cash flows with some growth optionality, Tokio Marine is worth a closer look.

Tokio Marine’s Re New push and M&A hunt could be reshaping a steady dividend story into something bigger, while its exposure to catastrophe and credit risk adds a twist the analysis report for Tokio Marine Holdings

Daiichi Sankyo Company (TSE:4568)

Overview: Daiichi Sankyo Company is a global pharmaceutical business focused on high margin oncology drugs such as Enhertu and Datroway, alongside treatments for cardiovascular disease, diabetes, migraine, osteoporosis and vaccines. These established medicine franchises create the earnings base that can support a covered, stable dividend, even though pharmaceuticals are not usually viewed as classic high yield income stocks.

Operations: Daiichi Sankyo generates all of its revenue from its Pharmaceutical Operation segment, which produced about ¥2,223,188 million in sales.

Market Cap: ¥4,842b

Income focused investors may pay attention to Daiichi Sankyo Company because its oncology portfolio, including approvals and label expansions for Enhertu and Datroway through mid 2026, is building a revenue stream that can underpin its 3.71% dividend yield. The company has a pipeline in antibody drug conjugates and global partnerships with groups like AstraZeneca and Innovent, which support scale and access across major markets. At the same time, reliance on a few blockbuster drugs, rising R&D spending and pressure on global drug pricing mean dividend coverage and free cash flow quality may matter more here than in a typical utility or consumer payer. The mix of income potential and concentration risk makes this a stock that some investors might research further.

Daiichi Sankyo Company’s accelerating oncology story and 3.71% yield look powerful together. Yet the real twist may lie in how concentrated that engine is. Get the full context in the full narrative for Daiichi Sankyo Company

Seeking Fresh Alternatives Before They Break Out

Some stocks are already building quiet momentum while most investors are still focused elsewhere. Before these ideas stop looking under the radar for now, scan the opportunities and act promptly.

• Spot resilient operators that could hold up when others wobble by checking companies in the 60 resilient stocks with low risk scores while they are still flying under most radars.
• Explore the potential next leg of the AI breakout by zeroing in on profitable operators through the curated 75 profitable AI stocks that aren't just burning cash before sentiment and prices really start moving.
• Follow early movers in critical infrastructure by tracking companies inside the 39 power grid technology and infrastructure stocks while the theme is still building and pricing has not fully caught up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com